Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Rifampicin PK/WBA in Healthy Volunteers
NCT02387242Phase 1Suspended
- Sponsor
- National University Hospital
- Start
- Feb 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rifampicin in Tuberculosis (TB) (3 arms), sponsored by National University Hospital. Primary endpoint: Cumulative Whole Blood Bactericidal Activity at 24 hours. Started Feb 2015; status: suspended.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02387242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387242.